trending Market Intelligence /marketintelligence/en/news-insights/trending/tsPVlUmg9rWPMogV0b16HQ2 content esgSubNav
In This List

Report: Valeant considers selling eye surgery biz to Carl Zeiss

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Report: Valeant considers selling eye surgery biz to Carl Zeiss

Valeant Pharmaceuticals International Inc. is in discussions to sell its unit Bausch & Lomb's eye surgery products business to Germany's Carl Zeiss Meditec AG, Bloomberg News reported, citing people familiar with the matter.

The assets could be valued about $2 billion in a potential deal, the sources reportedly said.

Negotiations are ongoing, and no decisions have been made. Other bidders could also step up, according to the report.